BioCryst announces FY2023 ORLADEYO revenue $325M (+29%), 2024 guidance $380-400M, sees operating profit in 2024

BIOCRYST PHARMACEUTICALS INC

2023-FY EPS reported -$1.18 revenue$331,412,000

Preliminary Q4 ORLADEYO net revenue $89.9M (+27% YoY); full-year 2023 $325M (+29% YoY).
2024 ORLADEYO revenue guidance $380-400M; company reaffirms peak sales target of $1B.
2024 operating expenses expected flat at $365-375M; R&D reduced $20M vs 2023.
Restructuring reduces workforce by 59 jobs (10%); plans to out-license BCX10013 if data supports.
ORLADEYO WAC increased ~5% to $42,366 per 28-day pack, effective January 8, 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

BIOCRYST PHARMACEUTICALS INC reported full year 2024 results: revenue 380-400. Guidance reaffirmed.

Period: full year 2024
Revenue: 380-400
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Guidance and Accelerated Path to Profitability —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales— —Operating expenses expected to remain flat ($365-$375 million) in 2024— —Company expects operating profit in

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-24-000112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.